Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jul 6;74(12):2129-2135.
doi: 10.1093/cid/ciab841.

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis

Paul Nyirjesy  1 , Jane R Schwebke  2 , David A Angulo  3 , Itzel A Harriott  3 , Nkechi E Azie  3 , Jack D Sobel  4
Affiliations
Clinical Trial

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis

Paul Nyirjesy et al. Clin Infect Dis. .

Abstract

Background: Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles. Ibrexafungerp, a novel, first-in-class oral triterpenoid glucan synthase inhibitor, has demonstrated broad fungicidal Candida activity and a favorable tolerability profile. The primary objective of this dose-finding study was to identify the optimal dose of oral ibrexafungerp in patients with acute vulvovaginal candidiasis.

Methods: Patients with vulvovaginal signs and symptoms score ≥7 were randomized equally to 6 treatments groups: 5 treatment doses of oral ibrexafungerp or oral fluconazole 150 mg. The primary endpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs and symptoms) at the test-of-cure visit (day 10).

Results: Overall, 186 patients were randomized into the 6 treatment groups. Results, using the modified intent-to-treat population (baseline positive culture), are reported for ibrexafungerp 300 mg twice daily (BID) for 1 day (n = 27), which was the dose selected for phase 3 studies, and fluconazole 150 mg for 1 day (n = 24). At day 10, the clinical cure rates for ibrexafungerp and fluconazole were 51.9% and 58.3%, respectively; at day 25, patients with no signs or symptoms were 70.4% and 50.0%, respectively. During the study ibrexafungerp patients required less antifungal rescue medications compared with fluconazole (3.7% vs 29.2%, respectively). Ibrexafungerp was well tolerated, with the most common treatment-related adverse events being mild gastrointestinal events.

Conclusions: Ibrexafungerp is a well-tolerated novel antifungal with comparable efficacy to fluconazole in the treatment of acute vulvovaginal candidiasis.

Clinical trials registration: NCT03253094.

Keywords: Candida albicans; SCY-078; fluconazole; ibrexafungerp; vulvovaginal candidiasis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient disposition. Abbreviations: BID, twice daily; QD, once daily.
Figure 2.
Figure 2.
Efficacy outcomes for ibrexafungerp 300 mg BID for 1 day from baseline to TOC (day 10), and follow-up (day 25) visits. A, Clinical cure, VSS scores ≤1, and rate of mycological eradication at TOC visit (day 10). B, VSS score of 0, VSS scores ≤1, and rate of mycological eradication at follow-up (day 25). C, Percentage of patients who required antifungal rescue medication while participating in the study. Clinical cure was defined as a complete resolution of VSS of acute vulvovaginal candidiasis at the TOC visit (day 10); the VSS scale is a standardized, predefined assessment for which each sign and symptom was given a numerical rating based on severity (absent = 0, mild = 1, moderate = 2, and severe = 3) to calculate a total composite score (range, 0–18); mycological eradication was defined as a negative fungal culture. Rescue medications used in these 2 treatment arms included fluconazole, Lotrisone (clotrimazole-betamethasone dipropionate), and terconazole. Abbreviations: BID, twice daily; TOC, test-of-cure; VSS, vulvovaginal signs and symptoms.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mendling W, Brasch J, Cornely OA, et al. . Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58:1–15. - PubMed
    1. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. . Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137. - PMC - PubMed
    1. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans Candida species in vulvovaginitis. J Fungi 2018; 4:121. - PMC - PubMed
    1. Jeanmonod R, Jeanmonod D.. Vaginal candidiasis. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459317/. Updated 21 November 2020. Accessed 9 December 2020.
    1. Committee on Practice Bulletins—Gynecology. Vaginitis in nonpregnant patients: ACOG practice bulletin, Number 215. Obstet Gynecol 2020; 135:e1–17. - PubMed

Publication types

Associated data